Weisbrod, Fine jump to hedge fund

Harpel Advisors, a New York-based hedge fund with $400 million under management, is stepping up its exposure in the broad area of health care, adding analysts Stuart Weisbrod and Robert Fine to its team. Weisbrod, formerly the senior biotechnology analyst at Merrill Lynch, joined Harpel at the start of the month. He will be joined as of March 1 by Fine, who had been the biotech analyst at Nomura Securities.

Maureen McGann, who already covers agbio companies Calgene Inc., DNA